- More Data on C. difficile and Pediatric IBD Outcomes
- Degree of Villous Atrophy and Outcomes in Children
- Impact of Serum ANA in Nonalcoholic Fatty Liver Disease
- Future High-Risk Adenomas After High-Risk Adenomas at Initial Screening
- Corticosteroids, TNF Antagonists and Outcomes from COVID-19 with IBD
- More Data on C. difficile and Pediatric IBD Outcomes
- Degree of Villous Atrophy and Outcomes in Children
- Impact of Serum ANA in Nonalcoholic Fatty Liver Disease
- Future High-Risk Adenomas After High-Risk Adenomas at Initial Screening
- Corticosteroids, TNF Antagonists and Outcomes from COVID-19 with IBD
- More Data on C. difficile and Pediatric IBD Outcomes
- Degree of Villous Atrophy and Outcomes in Children
- Impact of Serum ANA in Nonalcoholic Fatty Liver Disease
- Future High-Risk Adenomas After High-Risk Adenomas at Initial Screening
- Corticosteroids, TNF Antagonists and Outcomes from COVID-19 with IBD
Annual Advances in Inflammatory Bowel Diseases (AIBD) Conference AIBD 2020 VISION FOR THE NEXT DECADE
December 9 - December 12
Join us for the first-ever virtual Advances in Inflammatory Bowel Diseases (AIBD) conference. Over the last 19 years, AIBD has offered a distinguished level of forward-thinking, clinical education with real-world case studies, and access to leading experts from around the world committed to advancing the care and positive outcomes of patients with IBD. Although the format will be different, the level of high-caliber education delivered will remain unchanged.
The virtual conference will bring together all members in the IBD field—gastroenterologists, nurses, physicians, surgeons, and other healthcare professionals—to take part in a comprehensive program enhanced with progressive treatment strategies and new technology advances that are designed with your patients in mind. For more information, please visit: advancesinibd.com